$26.36
0.592.29%
At close: -
$26.36
0.000.00%
After Hours: 7:59 PM EDT
Comments
Loading...
Latest news for Pfizer (NYSE:PFE) Stock
Pfizer Stock (NYSE: PFE)
Categories: All
Friday, December 20, 2024
Thursday, December 19, 2024
Wednesday, December 18, 2024
Tuesday, December 17, 2024
- What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?
- Benzinga Market Summary: S&P Falls, Pfizer Ri...
- Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
- Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
- Pfizer CFO Does Not Expect Large Deals In 202...
- Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025
- Pfizer Expects No Material US Policy Changes ...
- Pfizer shares are trading higher after the co...
- Pfizer Reaffirms FY24 Outlook For Revenue Of ...
- Pfizer Says First Phase Of Manufacturing Opti...
- Pfizer Says It Achieved Goal Of $4B In Net Co...
- Pfizer Expects FY25 Revenue Of $61B - $64B (...
- Pfizer Provides Its Full-year 2025 Guidance A...
Monday, December 16, 2024
Friday, December 13, 2024
- Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children
- Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination
- Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
- "Weight-Loss Drug Craze Appears To Be Curbing...
Thursday, December 12, 2024
- Pfizer Increases Quarterly Cash Dividend From...
- Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
- Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
- Pfizer Announces Results From Phase 3 PATINA ...
- Pfizer's IBRANCE In Combination With Standard...
Wednesday, December 11, 2024
Tuesday, December 10, 2024
Sunday, December 08, 2024
Thursday, December 05, 2024
Wednesday, December 04, 2024
Tuesday, December 03, 2024
- Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments
- 'ADA Advises Against Using Compounded GLP-1 R...
- Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
- Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance